Gene therapy and angiogenesis in patients with coronary artery disease

References

• Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease – part I. Cardiol. Rev.16(4), 163–171 (2008).
   PubMed Web of Science ®Google Scholar
• Ahn A, Frishman WH, Gutwein A, Passeri J, Nelson M. Therapeutic angiogenesis: a new treatment approach for ischemic heart disease – part II. Cardiol. Rev.16(5), 219–229 (2008).
   PubMed Web of Science ®Google Scholar
• Taljaard M, Ward MR, Kutryk MJ et al. Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. Am. Heart J.159(3), 354–360 (2010).
   PubMed Web of Science ®Google Scholar
• Banai S, Jaklitsch MT, Shou M et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation89, 2183–2189 (1994).
   PubMed Web of Science ®Google Scholar
• Takeshita S, Zheng LP, Brogi E et al. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J. Clin. Invest.93, 662–670 (1994).
   PubMed Web of Science ®Google Scholar
• Schumacher B, Stegmann T, Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J. Cardiovasc. Surg.39, 783–789 (1998).
   PubMed Web of Science ®Google Scholar
• Sellke FW, Laham RJ, Edelman Er et al. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann. Thorac. Surg.65, 1540–1544 (1998).
   PubMed Web of Science ®Google Scholar
• Laham R, Sellke FW, Edelman ER et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery. Circulation100, 1865–1871 (1999).
   PubMed Web of Science ®Google Scholar
• Ruel M, Laham RJ, Parker JA et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J. Thorac. Cardiovasc. Surg.124, 28–34 (2002).
   PubMed Web of Science ®Google Scholar
• Laham RJ, Chronos NA, Marilyn P et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with ischemic heart disease: Results of a Phase I open-label dose escalation study. J. Am. Coll. Cardiol.36, 2132–2139 (2000).
   PubMed Web of Science ®Google Scholar
• Unger EF, Goncalves L, Epstein SE et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am. J. Cardiol.85, 1414–1419 (2000).
   PubMed Web of Science ®Google Scholar
• Simons M, Annex BH, Laham RJ et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2. Double-blind, randomized, controlled clinical trial. Circulation105, 788–793 (2002).
   PubMed Web of Science ®Google Scholar
• Hendel RC, Henry TD, Rocha-Singh K et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation101, 118–121 (2000).
   PubMed Web of Science ®Google Scholar
• Henry TD, Annex BH, McKendall GR et al. for the VIVA Investigators. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation.107(10), 1359–1365 (2003).
   PubMed Web of Science ®Google Scholar
• Sato K, Laham RJ, Pearlman JD et al. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann. Thorac. Surg.70, 2113–2118 (2000).
   PubMed Web of Science ®Google Scholar
• Laitinen M, Hartikainen J, Hiltunen MO et al. Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. Hum. Gene Ther.11, 263–270 (2000).
   PubMed Web of Science ®Google Scholar
• Hedman M, Hartikainen J, Syvänne M et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia. Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation107, 2677–2683 (2003).
   PubMed Web of Science ®Google Scholar
• Grines CL, Watkins MW, Helmer G et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation105, 1291–1297 (2002).
   PubMed Web of Science ®Google Scholar
• Grines CL, Watkins MW, Mahmarian JJ et al. for the Angiogenic Gene Therapy (AGENT-2) study group. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol.42, 1339–1347 (2003).
   PubMed Web of Science ®Google Scholar
• Henry TD, Grines CL, Watkins MW et al. Effects of Ad5FGF-4 in patients with angina. An analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol.50, 1038–1046 (2007).
   PubMed Web of Science ®Google Scholar
• Kastrup J, Jørgensen E, Drvota V et al. ; the EUROINJECT ONE group. Intra-myocardial injection of genes by a novel percutaneous technique. Initial safety data in the EUROINJECT ONE study. Heartdrug1, 299–304 (2001).
   Google Scholar
• Baldazzi F, Jorgensen E, Ripa RS, Kastrup J. Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route. Eur. Heart J.29(15), 1819–1826 (2008).
   PubMed Web of Science ®Google Scholar
• Symes JF, Losordo DW, Vale PR et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg.68, 830–837 (1999).
   PubMed Web of Science ®Google Scholar
• Sylvén C, Sarkar N, Rück A et al. Myocardial doppler tissue velocity improves following myocardial gene therapy with VEGF-A165 plasmid in patients with inoperable angina pectoris. Coron. Artery Dis.12, 239–243 (2001).
   PubMed Web of Science ®Google Scholar
• Sarkar N, Rück A, Källner et al. Effects of intra myocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease – 12 months follow-up: angiogenic gene therapy. J. Intern. Med.250(5), 373–381 (2001).
   PubMed Web of Science ®Google Scholar
• Rosengart T, Lee LY, Patel SR et al. Angiogenesis gene therapy. Phase I assessment of direct intra-myocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation100, 468–474 (1999).
   PubMed Web of Science ®Google Scholar
• Fuchs S, Dib N, Cohen BM et al. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of cather-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease. Catheter. Cardiovasc. Interv.68, 372–378 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Arnold JMO, Gregoire J et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a Phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment. Gene Ther.13(21), 1503–1511 (2006).
   PubMed Web of Science ®Google Scholar
• Kastrup J, Jørgensen E, Fuchs S et al. A randomized, double-blind, placebo-controlled, multicenter study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease. The NOVA trial. EuroIntervention(2010) (In Press).
   Google Scholar
• Vale PR, Losordo DW, Milliken CE et al. Randomised, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients chronic myocardial ischemia. Circulation103, 2138–2143 (2001).
   PubMed Web of Science ®Google Scholar
• Losordo DW, Vale PR, Hendel RC et al. Phase 1/2 placebo-controlled, doubleblind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation105, 2012–2018 (2002).
   PubMed Web of Science ®Google Scholar
• Tio RA, Tan ES, Jessurun GA et al. PET for evaluation of differential myocardial perfusion dynamics after VEGF gene therapy and laser therapy in end-stage coronary artery disease. J. Nucl. Med.45(9), 1437–1443 (2004).
   PubMed Web of Science ®Google Scholar
• Kastrup J, Joergensen E, Rück A et al. for the EUROINJECT ONE Group. Direct intra-myocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable angina pectoris – a randomized double-blind placebo-controlled study. The EUROINJECT ONE Trial. J. Am. Coll. Cardiol.45, 982–988 (2005).
   PubMed Web of Science ®Google Scholar
• Gyöngyösi M, Khorsand A, Zamini S et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intra-myocardial injections of plasmid encoding VEGF A-165 in patients with chronic myocardial ischemia. Subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation112(Suppl I) I157–I165 (2005).
   Google Scholar
• Stewart DJ, Kutryk MJB, Fitchett D et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary artery disease: results of the NORTHERN trial. Mol. Med.17, 1109–1115 (2009).
   Google Scholar
• Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation103, 634–637 (2001).
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl Acad. Sci. USA98, 10344–10349 (2001).
   PubMed Web of Science ®Google Scholar
• Schächinger V, Assmus B, Britten MB et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial. J. Am. Coll. Cardiol.44, 1690–1699 (2004).
   PubMed Web of Science ®Google Scholar
• Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet367(9505), 113–121 (2006).
   PubMed Web of Science ®Google Scholar
• Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med.355(12), 1199–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Perin EC, Dohmann HF, Borojevic R et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation107, 2294–2302 (2003).
   PubMed Web of Science ®Google Scholar
• Haack-Sørensen M, Friis T, Kastrup J. Mesenchymal stromal cell and mononuclear cell therapy in heart disease. Future Cardiol.4, 481–494 (2008).
   PubMedGoogle Scholar
• Mathiasen AB, Haack-Sørensen M, Kastrup J. Mesenchymal stromal cells for cardiovascular repair: current status and future challenges. Future Cardiol.5, 605–617 (2009).
   PubMedGoogle Scholar
• Wang Y, Tägil K, Ripa RS et al. Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int. J. Cardiol.100, 477–483 (2005).
   PubMed Web of Science ®Google Scholar
• Hill JM, Syed MA, Arai AE et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J. Am. Coll. Cardiol.46, 1643–1648 (2005).
   PubMed Web of Science ®Google Scholar
• Zohlnhöfer D, Dibra A, Koppara T et al. Stem cell mobilisation by G-CSF for myocardial recovery after acute myocardial infarction: a meta-analysis. J. Am. Coll. Cardiol.51(15), 1429–1437 (2008).
   PubMed Web of Science ®Google Scholar
• Ripa RS, Jørgensen E, Wang Y et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction. Result of the Double-Blind, Randomized, Placebo-Controlled Stem Cells in Myocardial Infarction (STEMMI) Trial. Circulation113, 1983–1992 (2006).
   PubMed Web of Science ®Google Scholar
• Kawamoto A, Murayama T, Kusano K et al. Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation110, 1398–1405 (2004).
   PubMed Web of Science ®Google Scholar
• Ripa R, Wang Y, Jørgensen E, Johnsen HE, Hesse B, Kastrup J. Direct intra-myocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor treatment to mobilize stem cells and promote myocardial homing to induce angiogenesis in patients with severe chronic ischemic heart disease. Eur. Heart J.27(15), 1785–1792 (2006).
   PubMed Web of Science ®Google Scholar
• Isner JM, Vale PR, Symes JF, Losordo DW. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ. Res.89, 389–400 (2001).
   PubMed Web of Science ®Google Scholar
• Wang Y, Johnsen HE, Mortensen S et al. Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. Heart92(6), 768–774 (2006).
   PubMed Web of Science ®Google Scholar
• Wang Y, Gabrielsen A, Lawler PR et al. Myocardial gene expression of angiogenic factors in human chronic ischemic myocardium – influence of acute ischemia/cardioplegia and reperfusion. Microcirculation13, 187–197 (2006).
   PubMed Web of Science ®Google Scholar
• Abbott JD, Huang Y, Liu D, Hickey R, Krause DS, Giordano FJ. Stromal cell-derived factor-1α plays a critical role in stem cell recruitment to the heart after myocardial infarction but is not sufficient to induce homing in the absence of injury. Circulation110, 3300–3305 (2004).
   PubMed Web of Science ®Google Scholar
• Hiasa K, Ishibashi M, Ohtani K et al. Gene transfer of stromal cell-derived factor-1α enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation109, 2454–2461 (2004).
   PubMed Web of Science ®Google Scholar
• Yang J, Zhou W, Zheng W et al. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology107, 17–29 (2007).
   PubMed Web of Science ®Google Scholar
• Yau TM, Kim C, Ng D et al. Increased transplanted cell survival with cell-based angiogenic gene therapy. Ann. Thorac. Surg.80, 1779–1786 (2005).
   PubMed Web of Science ®Google Scholar
• Heiss C, Keymel S, Niesler U et al. Impaired progenitor cell activity in age-related endothelial dysfunction. J. Am. Coll. Cardiol.45, 1441–1448 (2005).
   PubMed Web of Science ®Google Scholar
• Kobulnik J, Kuliszewski MA, Stewart DJ, Lindner JR, Leong-Poi H. Comparison of gene delivery techniques for therapeutic angiogenesis ultrasound-mediated destruction of carrier microbubbles versus direct intramuscular injection J. Am. Coll. Cardiol.54(18), 1735–1742 (2009).
   PubMed Web of Science ®Google Scholar